BioXcel Therapeutics

Yahoo Finance • 10 months ago

BioXcel Therapeutics to Host Virtual Neuroscience R&D Day on Dec. 12, 2023

Company to review BXCL502 and other potential emerging pipeline candidates Dr. Jeffrey Cummings to discuss agitation relief in Alzheimer’s disease and BXCL502 as a potential treatment Dr. Sandra Comer to discuss BXCL501 as a potential tr... Full story

Yahoo Finance • 10 months ago

BioXcel Therapeutics Inc (BTAI) Reports Q3 2023 Financial Results and Strategic Updates

BioXcel Therapeutics Inc (NASDAQ:BTAI) aligns with FDA for Phase 3 trial in TRANQUILITY program. Strategic financing terms agreed with Oaktree Capital Management and Qatar Investment Authority. Net revenue from IGALMI reported at approxima... Full story

Yahoo Finance • 10 months ago

BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial Results

Company plans to conduct Phase 3 trial of BXCL501 in the at-home setting for TRANQUILITY program to support potential sNDA for acute treatment of agitation associated with dementia due to probable Alzheimer’s disease Potential market oppo... Full story

Yahoo Finance • 10 months ago

BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) of Adenocarcinoma Phenotype

Median overall survival of 15.5 months with BXCL701 + KEYTRUDA® (pembrolizumab), compared to 9.6 months with checkpoint inhibitor monotherapy in late-line refractory patients in separate Phase 2 trial1 59% of studied patients alive at one... Full story

Yahoo Finance • 10 months ago

BioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501 (sublingual dexmedetomidine) for Potential Treatment of Opioid Use Disorder (OUD)

Columbia University-led trial expected to add fourth site to target completion of 4-arm, 160-patient trial in 2024 Fentanyl adulterated or associated with xylazine (FAAX) designated an emerging threat by the White House Office of National... Full story

Yahoo Finance • 11 months ago

BioXcel Therapeutics Receives Permanent J-Code for IGALMI™ (dexmedetomidine) Sublingual Film from Centers for Medicare & Medicaid Services

Standardizes and improves product reimbursement process New HCPCS Level II code J1105 to be effective January 1, 2024 NEW HAVEN, Conn., Oct. 30, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical co... Full story

Yahoo Finance • 11 months ago

BioXcel Therapeutics Announces Positive Findings from Independent Third Party Audit of Data Integrity at TRANQUILITY II Phase 3 Trial Site

No evidence of misconduct or fraud found beyond instance previously reported1 No findings identified that impact data integrity Company believes audit findings support reliability of positive TRANQUILITY II trial data and potential sNDA... Full story

Yahoo Finance • 11 months ago

Investors in BioXcel Therapeutics, Inc. (NASDAQ: BTAI) should contact the Shareholders Foundation in connection with a Lawsuit

SAN DIEGO, Oct. 10, 2023 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of BioXcel Therapeutics, Inc. (NASDAQ: BTAI). Investors, who purchased BioXcel Therapeuti... Full story

Yahoo Finance • 11 months ago

BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Small Cell Neuroendocrine Prostate Cancer

Median overall survival of 13.6 months with BXCL701 +KEYTRUDA® (pembrolizumab), compared to 7.6 months with checkpoint inhibitor monotherapy (CPI) in late-line refractory patients in separate, Phase 2 trial1 56% of studied patients alive... Full story

Yahoo Finance • 12 months ago

BioXcel Therapeutics Provides Update on Recent Developments for Late-Stage Clinical Programs and Expansion of IP Portfolio for IGALMI™ (dexmedetomidine) Sublingual Film

Meetings scheduled with FDA in October and November for TRANQUILITY and SERENITY III programs Company strengthens IGALMI™market exclusivity through receipt of two Notices of Allowance NEW HAVEN, Conn., Oct. 04, 2023 (GLOBE NEWSWIRE) --... Full story

Yahoo Finance • 12 months ago

Lifshitz Law PLLC Announces Investigations of ImmunityBio, Inc. (NASDAQ: IBRX), BioXcel Therapeutics, Inc. (NASDAQ: BTAI), Baxter International Inc. (NYSE: BAX)

NEW YORK, Sept. 30, 2023 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. (NASDAQ: IBRX) Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that th... Full story

Yahoo Finance • 12 months ago

Investigation Alert BAX, DHR, BTAI, and IBRX: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below

SAN DIEGO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Baxter International, Inc. (NYSE: BAX) Johnson Fistel, LLP is investigating potential claims on behalf of Baxter International, Inc. (NYSE: BAX). If you are a current, long-term shareholde... Full story

Yahoo Finance • last year

SHAREHOLDER ALERT: Levi & Korsinsky Notifies BioXcel Therapeutics, Inc.(BTAI) Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to... Full story

Yahoo Finance • last year

DEADLINE ALERT for BTAI, MNK, and STX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

LOS ANGELES, Sept. 05, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the... Full story

Yahoo Finance • last year

FINAL DEADLINE REMINDER FOR BTAI INVESTORS: Kessler Topaz Meltzer & Check, LLP Announces Final Lead Plaintiff Deadline in Securities Class Action Lawsuit Filed Against BioXcel Therapeutics, Inc. (BTAI)

RADNOR, Pa., Sept. 04, 2023 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Distric... Full story

Yahoo Finance • last year

Lifshitz Law PLLC Announces Investigations of Arrow Financial Corp. (NASDAQ: AROW), ImmunityBio, Inc. (NASDAQ: IBRX), BioXcel Therapeutics, Inc. (NASDAQ: BTAI), and Baxter International Inc. (NYSE: BAX)

NEW YORK, Sept. 02, 2023 (GLOBE NEWSWIRE) -- Arrow Financial Corp. (NASDAQ: AROW) Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations tha... Full story

Yahoo Finance • last year

BTAI 截止日期提醒：專業投資者法律顧問 ROSEN 鼓勵損失超過 10 萬美元的 BioXcel Therapeutics, Inc. 投資者在 9 月 5 日證券集體訴訟的重要截止日期前聘請律師 – BTAI

紐約, Sept. 03, 2023 (GLOBE NEWSWIRE) -- 事因：全球投資者權益律師事務所 Rosen Law Firm 提醒在 2021 年 12 月 15 日至 2023 年 6 月 28 日期間（含上述兩日，簡稱「集體訴訟期」）購買 BioXcel Therapeutics, Inc. (NASDAQ: BTAI) 證券之人士注意，首席原告的重要截止日期為 2023 年 9 月 5 日。 影響：若您在集體訴訟期內曾購買 BioXcel Ther... Full story

Yahoo Finance • last year

BTAI DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important September 5 Deadline in Securities Class Action – BTAI

NEW YORK, Sept. 01, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) between December 15, 2021 and June 28, 2023, both dates in... Full story

Yahoo Finance • last year

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioXcel Therapeutics, Inc. - BTAI

NEW YORK, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI).   Such investors are advised to contact Robert S. Willou... Full story

Yahoo Finance • last year

DEADLINE ALERT for BTAI, MNK, STX, BAX: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

BENSALEM, Pa., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the d... Full story